[
  {
    "ts": null,
    "headline": "Harbor Large Cap Value Fund Q4 2025 Portfolio Review",
    "summary": "Harbor Large Cap Value Fund Q4 2025 Portfolio Review",
    "url": "https://finnhub.io/api/news?id=be88801f6cd34ab8b8d2e34d4786cbb9eba1cfe6fc396424d3a73ea62e894da0",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771823520,
      "headline": "Harbor Large Cap Value Fund Q4 2025 Portfolio Review",
      "id": 139182518,
      "image": "",
      "related": "AMGN",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=be88801f6cd34ab8b8d2e34d4786cbb9eba1cfe6fc396424d3a73ea62e894da0"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk sinks 15% after weight loss drug fails to match Eli Lilly's in trial",
    "summary": "Novo Nordisk stock fell 15% Monday after it said its next-generation weight loss drug didn't meet its primary target.",
    "url": "https://finnhub.io/api/news?id=adb46c1fb7d8aa3447f4b0c93366d841ae4fcf0e75cdd60bdb482a92eb48a14e",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771822420,
      "headline": "Novo Nordisk sinks 15% after weight loss drug fails to match Eli Lilly's in trial",
      "id": 139185849,
      "image": "https://image.cnbcfm.com/api/v1/image/108226736-1763385463345-gettyimages-2244595163-DENMARK_DOUSTDAR.jpeg?v=1771844458&w=1920&h=1080",
      "related": "AMGN",
      "source": "CNBC",
      "summary": "Novo Nordisk stock fell 15% Monday after it said its next-generation weight loss drug didn't meet its primary target. ",
      "url": "https://finnhub.io/api/news?id=adb46c1fb7d8aa3447f4b0c93366d841ae4fcf0e75cdd60bdb482a92eb48a14e"
    }
  },
  {
    "ts": null,
    "headline": "1 Unpopular Stock That Deserves a Second Chance and 2 We Turn Down",
    "summary": "Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can jeopardize their other revenue-generating business lines like M&A advisory.",
    "url": "https://finnhub.io/api/news?id=25f06a5b5060c273b3ec8ee915cc1786b8c52d9acbba6415e68da4c71d6ae2cc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771822319,
      "headline": "1 Unpopular Stock That Deserves a Second Chance and 2 We Turn Down",
      "id": 139183073,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can jeopardize their other revenue-generating business lines like M&A advisory.",
      "url": "https://finnhub.io/api/news?id=25f06a5b5060c273b3ec8ee915cc1786b8c52d9acbba6415e68da4c71d6ae2cc"
    }
  },
  {
    "ts": null,
    "headline": "Barclays Begins Amgen (AMGN) Coverage, Notes Balanced Outlook Despite Trial Debate",
    "summary": "Amgen Inc. (NASDAQ:AMGN) is included among the 13 Best NASDAQ Dividend Stocks to Buy Now. On February 20, Barclays initiated coverage of Amgen Inc. (NASDAQ:AMGN) with an Equal Weight rating and a $185 price target. The analyst said there is still “plenty of time” before the Phase 3 MARITIME trial results are released, which means […]",
    "url": "https://finnhub.io/api/news?id=d1433600689d986bba476dca9f3a1583a3296699e18cab9675878d5aa23bd1a0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771813531,
      "headline": "Barclays Begins Amgen (AMGN) Coverage, Notes Balanced Outlook Despite Trial Debate",
      "id": 139180596,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen Inc. (NASDAQ:AMGN) is included among the 13 Best NASDAQ Dividend Stocks to Buy Now. On February 20, Barclays initiated coverage of Amgen Inc. (NASDAQ:AMGN) with an Equal Weight rating and a $185 price target. The analyst said there is still “plenty of time” before the Phase 3 MARITIME trial results are released, which means […]",
      "url": "https://finnhub.io/api/news?id=d1433600689d986bba476dca9f3a1583a3296699e18cab9675878d5aa23bd1a0"
    }
  }
]